

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb329</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Mokhtari</surname><given-names>Ehsan</given-names></name></contrib><aff>Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff>Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff>Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mokhtari</surname><given-names>Hesamodin</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Moslemi</surname><given-names>Elham</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>10</volume>
      <issue>4</issue>
      <fpage>227</fpage>
      <lpage>232</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>3</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>8</month>
          <year>2017</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: The Human Epidermal growth factor Receptor-3 (HER-3) is a member of ErbB receptor family and has deficient kinase activity. HER-3 should heterodimerize with other members of ErbB receptor family, especially with HER-2, to transduce downstream signaling pathways. HER-3 co-expresses with other ErbB receptors in different cancers and overexpresses while the oncogenic signaling pathways such as Jak/Stat, MAPK, and PI3K/Akt are activated and promoted. Here, the expression level of HER-3 was evaluated in Iranian gastric adenocarcinoma&amp;#39;s patients and the effects of HER-3 knocking down was investigated on cell cycle and cell viability of human gastric adenocarcinoma cell line of MKN45.&lt;br /&gt;
Methods: In this study, 38 paraffin-embedded surgical adenocarcinoma specimens and their marginal non-tumor tissue samples were collected. Total RNAs were extracted and cDNAs were synthesized. Finally, the expression level of HER-3 was evaluated by real time PCR approach. Moreover, the human adenocarcinoma cell line of MKN45 was transfected with siRNA against HER-3 and the effects of its down-regulation were evaluated using MTT assay and cell-cycle analysis.&lt;br /&gt;
Results: The data obtained from this study revealed HER-3 is significantly overexpressed in gastric tumors rather than non-tumor marginal tissues. Also, it was found that the expression level of HER-3 is elevated with tumor depth of invasion. Moreover, HER-3 knocking down promotes cell accumulation in G2/M phase of cell cycle and decreases cell viability in MKN45 cells which suggests a potential role for HER-3 in gastric adenocarcinoma tumorigenesis.&lt;br /&gt;
Conclusion: Taken together, these results emphasize the importance of HER-3 receptor in diagnosis and prognosis of gastric adenocarcinoma.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
